The template is global. The regulator, the code and the reviewer are not.
Affiliate sites have to deliver local language, local product information and local promotional compliance inside a template designed elsewhere — without asking for an exception that will never be granted.
A global site is written for a market with its own regulatory environment, and translating it wholesale imports assumptions that do not hold: indications approved elsewhere, patient-facing material prohibited locally, references to services that do not exist in your country. The work is one of selection and adaptation rather than of language — deciding what applies, what must be replaced with the local product information, and what cannot be published at all. Framing it as translation is how affiliates end up publishing content their own regulatory colleagues would never have approved.
The summary of product characteristics and the patient leaflet differ by market for the same molecule, and they are updated on a local cycle. Where the affiliate site carries a translated copy of the global version, it will diverge from the authorised local text, and it will do so silently. Connecting the site to the local authorised source, so the current document is served and a change propagates automatically, removes a recurring compliance exposure that manual processes have repeatedly failed to contain across this sector.
Which content requires a professional to identify themselves, how rigorously, and what may be shown to the public varies substantially between markets. A single global gating rule is therefore either too strict — hiding material that could legitimately be public locally and losing all its visibility — or too permissive, which is worse. Making the gating rule a market-level configuration rather than a global constant lets each country meet its own requirement precisely, and it is usually achievable within a global platform without asking for a structural exception.
Where several affiliates publish in the same language, search engines need explicit signals about which version serves which country. Without them the versions compete, one market’s page ranks in another, and a clinician may read an indication or an access arrangement that does not apply where they practise. This is configuration rather than content, it is frequently wrong in large multi-affiliate estates, and correcting it lifts every market at once — which makes it the most efficient technical work available to an affiliate team.
Local promotional review, the applicable industry code and local regulatory sign-off determine what an affiliate can publish, and those reviewers are already at capacity. A localisation plan that assumes a steady flow of newly approved pages will stall and leave a site visibly abandoned. Building around what the review process can genuinely absorb, reusing already-approved statements wherever the claim is unchanged, and getting templates approved once rather than page by page, is what keeps an affiliate site current after the launch.
Requests that require changing the global platform, the design system or the approval workflow tend not to survive governance. Requests to add local pages, local language and market-specific regulatory content within the existing components usually do. Establishing precisely where that line sits, and building to the edge of it, delivers most of the available value this quarter — while a proposal for a structural exception is still being discussed a year later. Affiliates consistently underestimate how much the template already allows.
What comes up when localising a global pharmaceutical site for a market.
Usually the local page inventory, the language, the market-specific regulatory and access content, and how the available components are assembled — which is more than most affiliate teams assume. Global governance generally protects brand presentation, claims and the core template rather than dictating which local pages exist. The affiliates that get the most out of this start by documenting exactly what the template permits and building to that edge, rather than treating the constraint as total.
No, and this is where affiliates most often get into difficulty. The global site reflects indications, claims and patient-facing rules for a different regulatory environment, and a faithful translation imports all of it. Product information has to come from your local authorised text, claims from what is approved in your market, and some global content simply cannot be published locally at all. It is a selection and adaptation exercise with translation as one part of it.
It should be configurable per market, because the requirements genuinely differ. A single strict global rule hides content that could be public in some countries, which costs visibility for no compliance benefit; a single permissive rule creates exposure in the markets with stricter requirements. Market-level configuration of the gating rule is normally achievable inside a global platform and does not require the structural exception that affiliates often assume it would.
By connecting the site to the local authorised document source rather than uploading copies. Manual processes fail predictably here — someone updates the leaflet in one place and not another, and an obsolete version stays live for months. Serving the current document from the controlled source means the site is correct as a consequence of the regulatory update rather than dependent on someone remembering, which is also the answer an auditor is looking for.
A translated global site carrying indications that are not approved here, a product leaflet two versions behind, and another market's page ranking for your country. Tell us which markets you cover and we will tell you what we would fix inside the template you already have.